silence therapeutics
silence therapeutics strives to conduct its business in an ethical, responsible and transparent manner .
silence therapeutics plc’s iss governance qualityscore as of n / a is n / a .
silence therapeutics develops these structural modifications using three exclusive licences from the university of massachusetts .
arrowhead nets $ 9. 6m investment from u. k. - based silence therapeutics
silence therapeutics daily update: silence ther. is listed in the pharmaceuticals & biotechnology sector of the london stock exchange with ticker
glassdoor gives you an inside look at what it' s like to work at silence therapeutics, including salaries, reviews, office photos, and more. this is the silence therapeutics company profile. all content is posted anonymously by employees working at silence therapeutics .
silence therapeutics share price. sln - stock quote, charts, trade history, share chat, financials. silence ther. ord 5p
xconomy: arrowhead nets $ 9. 6m investment from u. k. - based silence therapeutics
silence therapeutics website uses cookies. by continuing to browse you are agreeing to our use of cookies .
silence therapeutics is an aim listed biotechnology company focused on the discovery, delivery and development of novel rna therapeutics for the treatment of serious diseases with unmet medical need .
aim - quoted rna therapy specialist silence therapeutics plc (lon: sln) has bolstered its patent protections in the united states .
, chief scientific officer of silence, said :
these notifications from the uspto further strengthens silence' s ip position in the arena of rnai therapeutics and builds upon the already strong proprietary technology silence offers its partners. the broad range of rnai therapeutics in terms of their possible length of base pairs again distinguishes silence from competitors which provide coverage for only very few lengths, if any .
silence therapeutics plc on thursday said it notes a press release from quark pharmaceuticals inc, reporting positive results from a phase 2 ...
silence therapeutics is focused on the discovery, delivery and development of novel rna therapeutics for the treatment of serious diseases with unmet medical need. using its proprietary rna interference (rnai) technology and delivery systems, the company has a strategy of creating a new generation of therapeutics to help patients and grow shareholder value .
i applied through college or university. the process took 5 days. i interviewed at silence therapeutics (berlin (germany) ) in january 2013 .
the targeting, delivery and on - going structural modification of sequences are the three platforms for silence therapeutics’s rnai therapeutic development. these three platforms are :
london, uk & nijmegen / utrecht, netherlands, september 12, 2011 – silence therapeutics plc (aim: sln) (“silence”), a leading global rna interference (rnai) therapeutics company, and interna technologies b. v. (“interna”), a biopharmaceutical company developing pathway targeted microrna (“mirna”) - based therapeutics for cancer, today announce that they have entered into an agreement to develop novel microrna therapeutics for the treatment of cancer. this will combine the delivery capabilities of silence’s proprietary atuplex™ delivery system with interna’s novel micrornas .
silence therapeutics plc focuses on the discovery, development, and delivery of novel rna therapeutics. the company designs short interfering rna (sirna) molecules that trigger the rnai pathway and mediate the degradation of specific target messenger rnas. it is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases. the company was formerly known as sr pharma plc and changed its name to silence therapeutics plc in may 2007. silence therapeutics plc was incorporated in 1994 and is headquartered in london, the united kingdom .
silence therapeutics’ technology is protected by a valuable patent portfolio, which strengthens its competitive position within the industry and provides opportunities for licensing its technology to third - parties .
silence therapeutics has 781 number of twitter followers. the number of followers has grown 0. 6% month over month and grown 1. 9% quarter over quarter
silence therapeutics, a publicly traded biotech firm based in the u. k. , said it has made a $ 9. 6 million equity investment in arrowhead pharmaceuticals .
rna therapeutics company silence therapeutics plc (lse: sln) named dmitry samarsky cso, effective sept. 14. he was svp of technology and global business development at olix pharmaceuticals inc. (seoul, south korea). vaccine company paxvax inc. (redwood ...
we have developed proprietary modifications to improve the robustness of rna sequences, together with advanced liposomal chemistries to enhance the delivery of therapeutics. this allows the development of therapeutics for diseases with high unmet clinical need. silence’s technology is currently in the clinic in a phase 2a pancreatic cancer trial .
the company' s rnai therapeutic platform has received key validation through multiple partnerships with pharmaceutical companies including astrazeneca, dainippon sumitomo, pfizer / quark, and novartis / quark. silence is actively pursuing the establishment of additional partnerships. silence therapeutics has operations in both
silence therapeutics is a drug development company with a proprietary genetic medicine platform. silence operates in the maturing field or rna therapeutics, which harnesses the body’s natural mechanisms to create therapeutic effects within its cells. this technology can selectively silence or replenish the expression of any gene in the genome. we have developed proprietary modifications to improve the robustness of rna sequences, as well as advanced chemistries to enhance the effective delivery of therapeutic rna molecules to target cells .
forward - looking statements this press release includes forward - looking statements that are subject to risks, uncertainties and other factors. these risks and uncertainties could cause actual results to differ materially from those referred to in the forward - looking statements. all forward - looking statements are based on information currently available to silence therapeutics and silence therapeutics assumes no obligation to update any such forward - looking statements .
neuromuscular disease company sarepta therapeutics inc. (nasdaq: srpt) hired louise rodino - klapac as vp of gene therapy at its newly created gene therapy unit. she will continue to serve as acting cso at myonexus therapeutics inc. (new ...
the grant of us 9, 695, 423 is further confirmation by the us patent office of the validity of our patent claims that protect our innovative chemical modification technology, ” said ali mortazavi, silence therapeutics chief executive .
silence therapeutics’ rnai technology can selectively silence any gene in the genome, modulating gene expression down in a variety of organs and cell types, in vivo. the company has developed proprietary modifications to improve the robustness of rna sequences, as well as advanced chemistries to enhance the effective delivery of therapeutic rna molecules to target cells .
silence therapeutics plc (aim: sln), a leading rna interference (rnai) therapeutics company, today announced that the us patent and trademark office (uspto) has issued a notice of allowance indicating that it will grant patents based on two applications: 12 / 986, 389 and 13 / 230, 084. these cover respectively interfering rna molecules and lipid complexes used in drug delivery .
our mission is to use our technology to create a new generation of therapeutics which can improve outcomes for patients and, in the process, build shareholder value .
– potential for corporate activity. in our view, silence therapeutics’ current valuation should put the company on the radar of a number of potential suitors, whether they be in the rnai field already or looking to enter the sector by buying a valuable portfolio of rnai technology .
under the terms of the agreement, interna will provide silence with specific mirna sequences, which silence will formulate with its atuplex™ delivery system in order to develop multiple candidate drugs. silence and interna will undertake in vitro and in vivo studies of the candidate drugs developed under the agreement and select lead candidates for further evaluation. silence is eligible to receive upfront fees as well as staged research payments. further financial terms of the deal were not disclosed .
silence’s technology is clinical stage and is currently in active phase 2 and phase 3 trials carried out by a licensee .
silence said it believes that the granted patent claims are relevant to third party medicines that are in ongoing clinical trials .
silence therapeutics wants to put the kibosh on disease - causing genes. the company works in the field of rna interference (rnai), a cutting - edge approach to treating disease that involves interfering with, or silencing, targeted genes associated with disease. its atuplex drug ...
silence is currently conducting a phase i trial with atu027 in patients with advanced solid cancer. atu027 is based on silence´ proprietary atuplex™ delivery technology. interim data analysis from this trial were presented at the 2011 american society of clinical oncology conference and showed that atu027 is safe and well tolerated and provided broad support for atuplex™ as an effective sirna delivery technology with the potential to overcome the delivery challenges currently associated with rnai therapeutics .
supporting its ip portfolio, silence therapeutics has its own internally developed drug development programmes, along with a number of out - licenced programmes which use its technology. the company’s headline strategy is the development of its programmes, with highly stringent go / no - go criteria applied prior to making investment decisions .
the new us patent, ref 9, 695, 423, provides further protection for silence' s innovative chemical modification technology .
silence ther. has a 4 week average price of 134. 50p and a 12 week average price of 130. 50p .
the all - cash transaction could be a forerunner to discussions over a licensing deal or r & d collaboration, silence said. “we look forward to opening a constructive dialogue with arrowhead, ” ali mortazavi, silence’s ceo, said in a prepared statement .
interference (rnai) therapeutics for the treatment of serious diseases. rnai is a natural cellular process that occurs in almost all organisms and results in the silencing or shutting down of a target gene protein product. in an effort to combat a wide range of diseases, therapeutics that exploit the rnai process are being developed to halt the production of disease - causing proteins .
dr roel schaapveld, chief executive officer of interna technologies, said: “we are very excited about this collaboration with silence. working with atuplex™ and the experienced team at silence fits perfectly in our strategy to address the delivery challenge of rna based therapeutics upon systemic administration. atuplex™ may significantly contribute to the efficacy of several mirna drug candidates in our pipeline that have shown to reduce tumor growth in vivo and as such supports further development of these drug candidates towards the clinic. ”
the company has a history going back to january 1999 when atugen ag, a german biotechnology company focused on developing rnai therapeutics, was spun out of nasdaq listed ribozyme pharmaceuticals. in july 2005 atugen then completed the reverse takeover of aim listed sr pharma in conjunction with a £10 million fundraising and the business changed its name to silence therapeutics in may 2007 in order to reflect its increasing focus on rnai technology. the most recent capital raise was completed in may 2015, with a gross £40 million being raised via a fundraising at 240p per share .
our technology harnesses the body’s natural mechanisms to create therapeutic effects within its own cells. this technology can selectively silence or replace any ...
in april 2005 silence signed an option and licence agreement with quark pharmaceuticals giving quark access to the company’s aturnai® technology. there are currently four key programmes undergoing clinical trials which could create value for silence under the deal, in the near to medium - term, by generating milestone and royalty payments .
silence therapeutics plc (lse: sln), london, u. k. business: cancer, pulmonary date announced: 2015 - 04 - 08 type: placing to be raised: up to l40 million ($ 59. 7 million) shares: 16. 7 million price: 240p shares outstanding prior: 52. 1 million investor: institutional ...
silence committed a sizable chunk of its cash reserves with the deal. the company said it had about $ 58 million in cash as of last june .
silence therapeutics plc (lse: sln), london, u. k. business: cancer, renal, ophthalmic date announced: 2015 - 04 - 02 type: placing to be raised: up to l27. 3 million ($ 40. 5 million) shares: 11. 4 million price: 240p shares outstanding prior: 52. 1 million investor: ...
thomas christély, chief operating officer of silence therapeutics, said: “we are pleased to be collaborating with interna, and it is in our interest to broaden the potential value of our atuplex™ delivery system as a vehicle to modify gene expression using different oligonucleotide classes, alongside our continuing focus on our internal sirna therapies. functional delivery into target cells is one of the greatest challenges facing most nucleic acid therapies. silence remains committed to the development of its atuplex™ and other delivery systems including dacc and dbtc as it seeks to overcome these challenges. ”
“as previously stated, we will consider potential licences under our patent estate, which could have a significant financial effect relative to the current market capitalisation of silence .
we will consider potential licences under our patent estate, which could have a significant financial effect relative to the current market capitalisation of silence .
says ceo ali mortazavi
silence had been evaluating several different rnai - focused companies and technologies since raising the equivalent of about $ 48 million from investors in 2015, according to a news release .
silence therapeutics’ stake building comes in the midst of a difficult time for arrowhead in terms of its perception amongst investors and operational performance, the shares having fallen from just over 800 cents in august last year to their current levels of sub - 200 cents. this was primarily a result of arrowhead making the decision at the end of november to discontinue all three of its clinical programmes which utilised the firm’s proprietary delivery vehicle ex1 .
it is under this backdrop that silence decided in q2 2015 to increase investment in galnac - sirna conjugates for liver delivery. in april 2016 the company announced encouraging results from using an in - house structure, with potency observed believed to be competitive relative to peers. as a result, projects better suited to galnac will be transitioned to the technology, with liver therapeutics being a major focus for investment in the future. silence believes that its lipid nanoparticle delivery systems (above) are better suited to handling larger cargos, such mrna and for gene editing applications, with galnac best suited to rnai .
our technology is a highly specific and modular platform that enables us to inhibit or ‘silence’ the expression of disease - causing genes, allowing cells to revert to their healthy state .
the claims allowed on lipid complexes, the proprietary lipid which is a key element of silence' s drug delivery technology atufect, cover any composition irrespective of the class of compound to be delivered and irrespective of the disease to be treated. the patent will both extend and widen silence' s intellectual property ip related to the field of drug delivery .
david was appointed chief financial officer and company secretary of silence in july 2016. david holds a b. a. in english & philosophy from birmingham university, and is a qualified chartered accountant. prior to joining silence, david’s relevant biotech experience includes several senior finance roles within both uk and us publicly owned life science companies, most recently as senior eumea finance director for biomarin pharmaceuticals inc. from 2010 to 2016. prior to that he was cfo at plethora solutions plc (2008 - 2009), and group financial controller at ark therapeutics from 2001 to 2008, during which time ark undertook an ipo on the london stock exchange .
mortazavi told the financial news website proactive investors that silence intends to continue developing drugs on its own, rather than just buy other companies and have them perform the r & d work .
silence therapeutics plc is a united kingdom - based ribonucleic acid (rna) technology company. the company is primarily involved in the research and development of pharmaceutical products. the company' s technology harnesses the body' s natural mechanisms to create therapeutic effects within its own cells. the company has a has a genetic toolkit with its own therapeutic payloads to modulate gene expression up as well as down in preclinical in vivo models, and delivery systems for various organs and cell types .
silence therapeutics plc (formerly sr pharma plc, formerly stanford rook holdings plc) develops a new generation of medicines by harnessing the body' s natural mechanism of rna interference, or rnai, within its cells. its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease - causing proteins. using its enabling delivery systems, it has achieved an additional level of specificity by delivering our therapeutic rna molecules exclusively to target cells. silence' s proprietary rna chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life - threatening diseases .
we welcome the decision of the uspto on drug delivery as an appreciation of silence' s contribution. drug delivery is key for the therapeutic use of functional nucleic acid molecules such as sirna and mirna. with this patent, silence is becoming an even more attractive partner for companies interested in the delivery of a variety of classes of compounds with sirna and mirna being only two of them .
another delivery method being worked on by silence is “galnac”, a highly efficient, simple and specific delivery approach whereby a sugar molecule (n - acetylgalactosamine, galnac) is conjugated to the sirna molecule .
there are currently 70, 021, 624 shares in issue and the average daily traded volume is 5, 564 shares. the market capitalisation of silence ther. is £104, 332, 219. 76 .
the claims allowed on interfering rna molecules cover any double - stranded ribonucleic acid molecule where o - alkyl modified nucleotides are alternating with unmodified or differently modified nucleotides on both strands having a length of 17 to fewer than 30 ribonucleotides. this kind of modified double - stranded ribonucleic acid molecules form a key component of silence' s rnai therapeutics. the patent will extend silence' s intellectual property related to double - stranded ribonucleic acid molecules to include molecules of 17 to fewer than 30 base pairs in length for use in methods for the treatment of disease. importantly, the patent will protect any such double - stranded ribonucleic acid molecule across all therapy areas and cover double - stranded ribonucleic acid molecules irrespective of the specific nucleotide sequence used .
silence’s investment comes following its may 2015 fundraise, subsequent to which the company has been looking at a number of rnai assets within both listed and unlisted companies. proving further value creating opportunities, silence has stated that the investment in arrowhead is a precursor to potential future deals which could include product licensing, r & d collaboration, technology sharing or a potential corporate transaction (although no talks over a transaction are in progress at present) .
if a gene sends out too many mrnas (or “over - expresses” itself) a cell can produce too much of a certain protein, potentially leading to diseases such as cancer, diabetes and many others. rnai is the method used to reduce the number of mrnas which get translated to these disease causing proteins. it minimises the over - expression of genes – effectively turning off, or silencing (hence the name) the disease causing genes. it is this area upon which silence therapeutics is focused, having developed proprietary rnai molecules and delivery systems .
president and chief executive officer of plaquetec limited. non - executive director of ardelyx inc, iox therapeutics limited, oncimmune holdings plc, thrombolytic science international, phesi llc and avrobio inc. chair of vium inc, cocoon biotech inc and cell medica limited. committee member of the u. s. food & drug administration science board .
silence is the only listed rnai player in europe and a pioneer in this technology. through the efforts of our skilled scientists over the years we have established a robust platform that allows us to effectively trigger rnai in specific cell types .
silence said it acquired about 8. 4 percent of the outstanding shares of common stock in arrowhead (nasdaq: arwr), which is based in pasadena, ca, but houses its research and development team in madison, wi .
the trial met its primary endpoint, with no safety issues being identified for the combination of atu027 with chemotherapy drug gemcitabine. silence now intends to progress atu027 through a suitable partnership rather than using its cash resources to fully develop it itself .
sr pharma, which rose out of stanford rook ltd. and has since changed its name to silence therapeutics, is a biotechnology company which was developing treatments derived from heat - killed mycobacterium vaccae (nctc11659) and called srl172 or srp299 (depending on the manufacturing process used) in the 1990s. one of the founders of stanford rook, professor john stanford, helped dr charles akle to set up immodulon in 2007. immodulon bought the rights to m. vaccae and is now continuing development under the name imm‑201 using an improved manufacturing process and target indications which are more relevant to its known mode of action .
silence therapeutics shares currently trade at 89p, capitalising the company at £62. 1 million. with the last reported cash figure (£47. 59 million at as 30 th june 2016) being 8 months old, we estimate, based upon r & d and admin expenses being maintained at levels seen over the prior 18 months, and accounting for the transaction in arrowhead shares, that cash plus available for sale investments (arwr) currently stand at c. £43 million. thus, the markets are valuing the business, which incorporates the valuable intellectual property portfolio and programme of clinical trials, at just £19. 1 million .
our technology harnesses the body’s natural mechanisms to create therapeutic effects within its own cells. this technology can selectively silence or replace any gene in the genome, modulating gene expression up as well as down in a variety of organs and cell types, in vivo .
arrowhead, for its part, emphasized that silence’s investment is the only official business the two firms have done together up to this point. “there have been no discussions about any potential transaction between the two companies, ” arrowhead said in a separate news release .
at silence we are developing novel rnai based therapies with the potential to transform patients’ lives. we use our proprietary technology platform to advance the next generation of genetic medicines, designed to intervene at the root of the problem by targeting the expression of disease - causing genes .
the company’s patented rnai chemistry is known as aturnai®, a proprietary technology with which individual sirna molecules are stabilised against degradation within the body. it is made up of highly potent, chemically stabilised sirna molecules which offer greater stability and better tolerability over conventional sirna molecules. aturnai® is one of the most thoroughly tested rnai therapeutics in humans and has an excellent safety record, with over 400 people dosed so far .
silence’s current enterprise value should prove to be no problem for larger pharma industry players to pay. in particular, we note that alnylam, largely considered to be the market leader in galnac technology, had cash & marketable securities of $ 1. 04 billion as at 30 th september 2016 .
the delivery systems are subject to various patent families extending the scope of protection to the specific composition and use of the delivery systems. with the technologies able to deliver rna molecules to a wide variety of disease tissue silence has the opportunity to partner with other companies working in, or looking to enter, the rna field .
in interim results released last september the company revealed that in the previous six months it had obtained advice from three separate law firms indicating that multiple sirna based drugs currently in clinical development potentially fall within its issued claims. in reaction, silence has invited the relevant companies, which have remained un - named, to enter licensing negotiations .
settlement was recently reached over arbitration proceedings with quark over a milestone payment under the licensing deal in relation to qpi - 1002. following the agreement silence will now receive a $ 1 million cash payment and is also eligible to receive either c. 2% royalties plus milestones or 15% of the clinical, regulatory and commercial milestone payments and royalties received by quark from partner novartis .
it has at least put the brakes on the share price. who knows - if there' s any truth to the suggestions that alnylam might look to settle the patent dispute by taking over silence then now might be a good time to strike. certainly it seemed to me from the alnylam call that alnylam see the fitusiran death as tragic but by no means an end to their hopes for the drug .
arrowhead said on monday that it plans to continue development of several drug candidates, none of which are currently in clinical trials. the company is developing some candidates independently, but on others it is collaborating with partners, including amgen (nasdaq: amgn), a large pharmaceuticals company based in thousand oaks, ca. in its release announcing the investment from silence, arrowhead said it will “continue to seek partnerships and collaborations that maximize the value of its assets. ”
delivering sirna into the body has long been a challenge for the rnai industry. in order to exert its effects, sirna must be safely and efficiently delivered into the target cells within the body, penetrate the cell membrane and survive for a sufficient amount of time once inside the cell. to address this challenge silence has developed a number of core proprietary liposomal delivery systems atuplex®, dacc, hepaplex and macplex, focused on delivering its specially modified aturnai® molecules to a variety of organs .
silence is the only listed rnai player in europe and a pioneer in this technology. through the efforts of our skilled scientists over the years we have established a robust platform that allows us to effectively trigger rnai in specific cell types. our inventions are protected by a broad intellectual property estate, which is a fundamental asset. together with our progress, the fact that the field is generally maturing means that rnai drugs are close to becoming a powerful genetic medicine modality at the disposal of doctors and patients .
dr. jenkins is a biopharma thought leader with 25 years of industry experience. until november 2017, she was president and chief executive officer at leading gene therapy company, dimension therapeutics. prior to joining dimension in september 2014, annalisa served as head of global research and development at merck serono pharmaceuticals from 2013 to 2014, where she also served as executive vice president global development and medical from 2011 to 2013. prior to this, dr. jenkins held several leadership roles at bristol myers - squibb from 1997 to 2011, most recently serving as senior vice president and head of global medical affairs. earlier in her career, dr. jenkins was a medical officer in the british royal navy during the gulf conflict, achieving the rank of surgeon lieutenant commander .
in january 2009 quark announced the initiation of phase i / ii clinical trials for its drug candidate qpi - 1002 for the prevention of delayed graft function (dgf) in deceased donor adult kidney transplant patients. trials of the drug (which are in partnership with novartis and incorporate silence’s aturnai® technology) have progressed well, with phase iii trials in dgf, along with a phase ii study in acute kidney injury (aki), currently ongoing. both trials are expected to have readouts in mid - 2018, which provides a potential share price catalyst .
january this year saw silence use its cash resources to invest, on - market, in nasdaq listed arrowhead pharmaceuticals (nasdaq: arwr). as at 13 th january a 9. 21% equity stake in arrowhead had been acquired, which will be held as an investment asset on the balance sheet. a total of $ 11. 3 million was spent on the acquisition, equating to an average buying price of c. 165 cents per share. the shares currently trade at 212 cents, giving a gain on investment to date of c. 28% .
dr. andrew j. richards is non - executive chairman at ixico plc, chairman at abcodia ltd. , chairman at cambridge temperature concepts ltd. , chairman at congenica ltd. , chairman at novacta biosystems ltd. , council member at biotechnology & biological sciences research council and a member at biological sciences research council. he is on the board of directors at silence therapeutics plc, cancer research technology ltd. , cambridge university hospitals nhs foundation trust, croggan ltd. , ieso digital health ltd. , arecor ltd. , babraham bioscience technologies ltd. and british science association. dr. richards was previously employed as independent non - executive director by summit corp. plc, independent non - executive director by vectura group plc, non - executive director by biowisdom ltd. , director - business development by chiroscience group plc, executive director by chiroscience ltd. , non - executive director by aitua ltd. , chairman by altacor ltd. , a principal by astrazeneca plc, a member by cancer research uk, executive director by celltech plc, chairman by ixico ltd. , non - executive director by pharmakodex ltd. , and non - executive director by theradeas ltd. he also served on the board at amedis pharmaceuticals ltd. , cambridge biotechnology ltd. , daniolabs ltd. , electra - net group ltd. and the bioindustry association. he received his doctorate degree from the university of cambridge .
– negative investor sentiment towards the rnai sector presents buying opportunity. as we have discussed above with arrowhead, companies involved in the rnai sector have seen a number of setbacks in recent months. share prices amongst rnai companies have plummeted, including a c. 70% fall over the past 18 months for alnylam pharmaceuticals (alny: nasdaq) after the company announced the halting of several clinical trials. shares in dicerna pharmaceuticals (drna: nasdaq), which is being sued by alnylam for “trade secret misappropriation”, are down by c. 90% in just under two years and are currently trading at below cash. there is no negative read - across from any of these events to silence’s technology or activities in our view. thus, we believe that the present environment provides investors an opportunity to enter this highly prospective sector at a time when valuations are at the bottom of the cycle .
our management team is highly experienced in a variety of relevant sectors, from molecular biology and genetics to finance and investment banking .
our board of directors is formed by six accomplished members, two executive and four non - executive directors .
as the rna field evolves at an ever - faster rate, our tab helps us to assess its competitive position in technology and offers guidance in developing it in the most effective way .
we are committed to creating collaborations that maximise value for each of the partners .
effective sirna delivery to the right cells is a challenge given the complexity of the human body. discover how we address this .
find out more about our investment case, share price, corporate governance and related information. download our latest reports and announcements .
a summary of relevant information for our shareholders, investor faqs and key adviser details .
our upgraded, patient - friendly delivery technology is suitable for applications in a variety of disease settings. our liver centric pipeline is currently build around three main areas of high unmet need: haematology, metabolic and rare diseases .
we out - licensed our sirna stabilisation chemistry technology (aturnai tm) to quark pharmaceuticals, who have progressed drug candidates that use this technology to late clinical trials .
we have developed proprietary stabilising chemistries to improve the robustness of sirna sequences, together with advanced delivery systems that enable us to specifically target relevant cell types. this results in potent and highly specific drug candidates .
our inventions are protected by a broad intellectual property estate, which is a fundamental asset. together with our progress, the fact that the field is generally maturing means that rnai drugs are close to becoming a powerful genetic medicine modality at the disposal of doctors and patients .
we have out - licensed our sirna stabilisation chemistry technology (aturnai tm) to quark pharmaceuticals, who have progressed drug candidates that use this technology in late - stage clinical trials .
research in rnai has been progressing over the past 20 years, achieving nobel prize recognition in 2006, and can now be seen to be transitioning from the experimental realm into the clinical. it is not often as an employee that you get a chance to be part of a nascent field like this that will make an impact on medicine .
we offer a vibrant culture and environment where innovation and creativity is encouraged. small, dynamic, with slick decision making and unencumbered by bureaucracy, we recognise contributions wherever they may be made within our team. our focus is on results, and opportunities for early career progression are here for team members who exceed their goals .
we should also mention we hope to have a lot of fun on the way, fully embracing the multi cultural mix of the talented professionals we employ .
our teams are located in west london, which is our corporate headquarters, and berlin where the majority of our research & development staff are based .
please review our current vacancies which are listed below. we are also interested to hear from candidates on a speculative basis either via the enquiries box or via e - mail to
our management team is highly experienced in a variety of relevant sectors, from molecular biology and genetics to finance and investment banking. this combination of skill sets enables the team to effectively execute our business plan .
our business model is designed to bring solutions to patients while generating shareholder value, by translating our proprietary technology into commercial drug products in a rapid and cost - effective way .
our corporate governance framework is based on using the leadership provided by our board to drive the effective execution of our strategy, ensuring that risk is appropriately mitigated and managed .
we have three board committees (remuneration, audit and risk, and nominations), focused on providing the required oversight to maintaining the highest corporate governance standards. through these committees and regular interactions with the executive team, our board applies internal financial controls and approves the company’s policy and strategy .
the london stock exchange uses cookies to improve its website. the cookies for analytical purposes have already been set. for more details and how to manage cookies, please see our privacy and cookies policy .
as at 09 - jul - 2018 21: 00: 10 - all data delayed by at least 15 minutes .
* for instruments denominated in gbx, the trade value is shown in gbp when the traded currency is gbx or gbp. when the traded price is any other currency then the trade value is displayed in that currency .
* the company market capitalization reflects the london listed element of ordinary and preference shares only and is approximate. data provided by ftse russell .
the exchange accepts no responsibility for the content of the website you are now accessing or for any reliance placed by you or any person on the information contained on it .
by allowing this link the exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person .
the exchange accepts no responsibility for the content of the reports you are now accessing or for any reliance placed by you or any person on the information contained therein .
72 hammersmith road london w14 8th p: + 4420. 34576900 f: + 447. 957318494
reuters, the news and media division of thomson reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. reuters provides trusted business, financial, national, and international news to professionals via thomson reuters desktops, the world' s media organizations, and directly to consumers at urltoken and via reuters tv. learn more about thomson reuters products :
all quotes delayed a minimum of 15 minutes. see here for a complete list of exchanges and delays .
immuno - oncology company apeiron biologics ag (vienna, austria) hired peter llewellyn - davies as cfo and cbo. he was cfo and cbo at medigene ag (xetra: mdg1). infectious disease company tetraphase pharmaceuticals inc. (nasdaq: ttph) named kamalam unninayar cfo. she ...
neurological diseases play flex pharma inc. (nasdaq: flks) said christoph westphal will step down as ceo, effective july 3. he will remain chairman. president of r & d william mcvicar will be interim ceo. cancer company viratherapeutics gmbh (innsbruck, ...
gruenenthal group (aachen, germany) named gabriel baertschi ceo, effective oct. 1. he will replace eric - paul paques, who will retire. baertschi is country president for japan at astrazeneca plc (lse: azn; nyse: azn). cns play forum pharmaceuticals inc... .
final data from the phase iia portion of the open - label, german phase ib / iia atu027 - i - 02 trial in 23 patients with locally advanced or metastatic pancreatic adenocarcinoma showed that twice - weekly atu027 for 4 weeks plus once - weekly gemcitabine ...
having addressed one of the two big problems of rnai delivery - getting therapeutic levels of the molecules inside cells - arrowhead research corp. now believes it has solved the second, with a modification to ...
a post hoc analysis of the subgroup of 19 patients with metastatic pancreatic adenocarcinoma in the phase iia portion of the open - label, german phase ib / iia atu027 - i - 02 trial showed that twice - weekly atu027 for 4 weeks plus ...
news corp is a network of leading companies in the worlds of diversified media, news, education, and information services .
real - time u. s. stock quotes reflect trades reported through nasdaq only .
international stock quotes are delayed as per exchange requirements. indexes may be real - time or delayed; refer to time stamps on index quote pages for information on delay times .
quote data, except u. s. stocks, provided by six financial information .
data is provided
as is
for informational purposes only and is not intended for trading purposes. six financial information (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. data may be intentionally delayed pursuant to supplier requirements .
© thomson reuters. all rights reserved. any copying, republication or redistribution of lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of lipper. lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon .
for inquiries related to this message please contact support. for sales inquiries, please visit urltoken
if you believe this to be in error, please confirm below that you are not a robot by clicking
i' m not a robot
below .
please make sure your browser supports javascript and cookies and that you are not blocking them from loading. for more information you can review the terms of service and cookie policy .
dr. annalisa mary jenkins frcpc, mbbs, frcp, mrcp, f. r. c. p .
and compensation values are for the last fiscal year ending on that date. pay is salary, bonuses, etc. exercised is the value of options exercised during the fiscal year. currency in usd .
the pillar scores are audit: n / a; board: n / a; shareholder rights: n / a; compensation: n / a .
scores indicate decile rank relative to index or region. a decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk .
arrowhead research is focused on developing, commercializing, and licensing a range of nanotechnology products and applications .
sign up for a free crunchbase account to follow and track organizations you care about .
terms of service | privacy policy | © 2018 crunchbase inc. all rights reserved .
descriptive keyword for an organization (e. g. saas, android, cloud computing, medical device )
this field describes an organization' s most recent funding status (e. g. early stage venture, late stage venture, m & a )
last funding round type (e. g. series a, seed, private equity )
transaction name: auto - generated name of transaction (e. g. angel - uber )
transaction name: auto - generated name of transaction (e. g. whatsapp acquired by facebook )
glassdoor will not work properly unless browser cookie support is enabled. learn how to enable cookies .
explore the many benefits of having a premium branded profile on glassdoor, like increased influence and advanced analytics .
changes won' t be saved until you sign up for an enhanced profile subscription .
the cso at the time was a very good person and scientist that was always nice and make you feel comfortable. easy discussion with internal referral from university. easy question about lipids, sirna and oligonucleotide in general. german and english question. opportunity to come back after postdoc in the usa .
copyright © 2008–2018, glassdoor, inc .
glassdoor
and logo are proprietary trademarks of glassdoor, inc .
the company highlighted that chemical modification technology is vital to prevent the degradation of therapeutic short interfering rna (sirna) molecules and to enable potent rna interference (rnai), and as such it can have a substantial impact on the performance of rnai drugs .
the company is a publisher. you understand and agree that no content published on the site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. you further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter .
you understand that the site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the company. you understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. in cases where the position is held at the time of publication and such position is known to the company, appropriate disclosure is made. however, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. you understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the company, the information providers or any other person or entity, and may not be complete or accurate .
from time to time, reference may be made in our marketing materials to prior articles and opinions we have published. these references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. as markets change continuously, previously published information and data may not be current and should not be relied upon .
proactive investors limited, trading as “proactiveinvestors united kingdom”, is authorised and regulated by the financial conduct authority. registered in england with company registration number 05639690. group vat registration number 872070825 fca registration number 559082. you can contact us here. market indices, commodities and regulatory news headlines copyright © morningstar. data delayed 15 minutes unless otherwise indicated. terms of use
described as being one of the most important recent discoveries in life sciences, rnai can selectively suppress disease causing genes. it has the potential to create a new class of therapeutic products for a broad range of diseases, many of which have an unmet need .
first discovered in the late 1990s, rna interference (rnai) is a highly prospective and rapidly advancing area of biotechnology concerned with gene suppression, or “gene silencing” – a process which enables the regulation of gene expression (the process whereby information from a gene is used to produce proteins and rna). rnai is a naturally occurring process that occurs in organisms ranging from plants to mammals and can be utilised to selectively suppress the genes which cause certain diseases. this is done by preventing the over - expression of the gene and thus reducing the production of disease causing protein .
described as being one of the most important recent discoveries in life sciences, and one of the most exiting areas of drug discovery today, rnai technology has made significant leaps forward over the past decade, with the 2006 nobel prize in physiology or medicine being awarded to andrew fire and craig mello for, “their discovery of rna interference – gene silencing by double - stranded rna” .
having attracted the attention and investment of large pharma and other smaller specialist research companies, a number of rnai driven drugs are now moving to later stage clinical trials. however, the market remains at an early stage of development, with no rnai based drugs having been approved to date .
the nucleus of each living cell contains dna (deoxyribonucleic acid), where specific genes and their genetic codes are stored. dna is the blueprint for the manufacture of proteins, the building blocks of life which enable the body to function. to pass on its instructions, dna itself does not leave the cell nucleus but instead creates a temporary copy of its genetic information. this copy is known as messenger rna (mrna), an rna molecule which can leave the nucleus and transmits instructions to a cell’s ribosomes, the cell component responsible for synthesizing protein .
when rnai molecules are administered to patients they are absorbed into target cells. also known as short interfering rna (sirna), these molecules in effect carry the “anti - code” to that of the mrnas which are being over - produced. once the sirnas bind to the mrnas the genetic code has been “interfered” with and can no longer be translated for protein production. as a result, protein production reduces, improving the diseased state.
silence therapeutics ( aim : sln ) is a biotechnology company that develops gene therapeutic technology based on rna interference ( rnai ) . they are involved in developmental research of targeted rnai therapeutics for the treatment of serious diseases . formed in 1994 as a publicly traded drug research and development company , silence therapeutics has offices in london and berlin , with its corporate headquarters at 1 lyric square , london . 
silence therapeutics (aim: sln) is a biotechnology company that develops gene therapeutic technology based on rna interference (rnai). they are involved in developmental research of targeted rnai therapeutics for the treatment of serious diseases. formed in 1994 as a publicly traded drug research and development company, silence therapeutics has offices in london and berlin, with its corporate headquarters at 1 lyric square, london.
silence therapeutics (aim: sln) is a biotechnology company that develops gene therapeutic technology based on rna interference (rnai). they are involved in developmental research of targeted rnai therapeutics for the treatment of serious diseases. formed in 1994 as a publicly traded drug research and development company, silence therapeutics has offices in london and berlin, with its corporate headquarters at 1 lyric square, london.